All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Pfizer ( PFE, Financial) stock dropped more than 2% at the start of the stock market opening Tuesday after the company posted ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...